PubRank

Paolo Calabresi

Author PubWeight™ 161.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005 3.30
2 Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003 3.25
3 Ischemic bilateral hippocampal dysfunction during transient global amnesia. Neurology 2007 2.10
4 The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci 2011 1.76
5 Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord 2014 1.76
6 Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain 2011 1.75
7 Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 2003 1.66
8 Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry 2007 1.48
9 Cyclic vomiting syndrome, migraine, and epilepsy: a common underlying disorder? Headache 2003 1.47
10 Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol 2007 1.47
11 Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006 1.45
12 Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002 1.40
13 Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013 1.37
14 Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol 2002 1.36
15 A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 2006 1.34
16 Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 2003 1.31
17 Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008 1.31
18 Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 2005 1.26
19 Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011 1.25
20 Synaptic dysfunction in Parkinson's disease. Adv Exp Med Biol 2012 1.20
21 Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J Neurosci 2009 1.16
22 Plasticity and repair in the post-ischemic brain. Neuropharmacology 2008 1.16
23 Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory. Behav Brain Res 2008 1.15
24 Voltage-dependent membrane potential oscillations of rat striatal fast-spiking interneurons. J Physiol 2003 1.15
25 Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol 2004 1.15
26 Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci 2011 1.14
27 A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 2010 1.13
28 Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord 2007 1.13
29 A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission. Neuropsychopharmacology 2004 1.13
30 Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology 2002 1.13
31 Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. J Neurosci 2004 1.13
32 Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology 2002 1.10
33 Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 2009 1.09
34 Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 2007 1.07
35 Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 2008 1.07
36 Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 2004 1.06
37 Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev Neurosci 2003 1.06
38 Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 2012 1.05
39 Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2010 1.05
40 Cortical spreading depression as a target for anti-migraine agents. J Headache Pain 2013 1.03
41 Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. Eur J Neurosci 2002 1.02
42 Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007 1.00
43 Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache 2009 1.00
44 Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology 2012 1.00
45 Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 2005 1.00
46 Tissue plasminogen activator is required for corticostriatal long-term potentiation. Eur J Neurosci 2002 0.99
47 Occipital arteriovenous malformations and migraine. Cephalalgia 2011 0.97
48 Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004 0.97
49 Removing pathogenic memories: a neurobiology of psychotherapy. Mol Neurobiol 2005 0.97
50 Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging 2011 0.97
51 Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 2010 0.97
52 Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain 2012 0.96
53 Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol Dis 2013 0.96
54 Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis 2010 0.96
55 c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model. J Biol Chem 2011 0.96
56 NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke 2006 0.95
57 Inhibition of persistent sodium current fraction and voltage-gated L-type calcium current by propofol in cortical neurons: implications for its antiepileptic activity. Epilepsia 2005 0.95
58 Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 2010 0.95
59 Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. J Headache Pain 2014 0.94
60 Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 2005 0.94
61 Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov Disord 2013 0.94
62 Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia 2009 0.94
63 Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett 2008 0.94
64 Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 2007 0.94
65 CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis 2010 0.93
66 Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain 2004 0.93
67 Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci 2002 0.93
68 Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003 0.93
69 Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 2005 0.92
70 Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 2002 0.92
71 Application of the ICHD-II criteria to the diagnosis of primary chronic headaches via a computerized structured record. Headache 2007 0.92
72 Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study. Mov Disord 2007 0.92
73 Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006 0.91
74 Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007 0.91
75 Medication-overuse headache: pathophysiological insights. J Headache Pain 2005 0.91
76 l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2007 0.90
77 Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol Med 2007 0.90
78 Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke 2004 0.89
79 Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 2006 0.89
80 The brain cytoplasmic RNA BC1 regulates dopamine D2 receptor-mediated transmission in the striatum. J Neurosci 2007 0.88
81 Mortalin inhibition in experimental Parkinson's disease. Mov Disord 2011 0.88
82 Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. J Neurosci 2012 0.87
83 Chronic cocaine prevents depotentiation at corticostriatal synapses. Biol Psychiatry 2006 0.87
84 Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD. Parkinsonism Relat Disord 2008 0.86
85 Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. Neurosci Lett 2006 0.86
86 Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 2012 0.86
87 Immunological profile of silent brain infarction and lacunar stroke. PLoS One 2013 0.86
88 Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study. Purinergic Signal 2007 0.86
89 Application of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist. J Headache Pain 2005 0.86
90 Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. Eur J Neurosci 2009 0.85
91 Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009 0.85
92 BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. Nat Commun 2013 0.85
93 Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. Learn Mem 2004 0.84
94 Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide. Mov Disord 2008 0.84
95 Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol Cell Neurosci 2004 0.84
96 Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. Prog Neurobiol 2011 0.84
97 Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. Neurobiol Dis 2007 0.84
98 Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. Biol Psychiatry 2009 0.84
99 Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 2008 0.84
100 Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. Neurobiol Aging 2011 0.84
101 Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases. Biochim Biophys Acta 2009 0.83
102 Plastic abnormalities in experimental Huntington's disease. Curr Opin Pharmacol 2006 0.83
103 Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment. Biol Psychiatry 2010 0.83
104 Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis 2012 0.83
105 NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease. Neurosci Lett 2007 0.83
106 Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. J Neurosci 2012 0.83
107 Hippocampal enlargement in Bassoon-mutant mice is associated with enhanced neurogenesis, reduced apoptosis, and abnormal BDNF levels. Cell Tissue Res 2011 0.83
108 Acetyl-L-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine. Neuropharmacology 2006 0.82
109 Medication overuse headache: neurobiological, behavioural and therapeutic aspects. Pain 2010 0.82
110 Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Prog Brain Res 2010 0.82
111 Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia. Exp Neurol 2011 0.82
112 A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: modulation by zonisamide. Neurobiol Dis 2011 0.81
113 A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation. PLoS One 2012 0.81
114 Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. Neuropharmacology 2004 0.81
115 Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Epilepsy Res 2008 0.81
116 Complexity of motor sequences and cortical reorganization in Parkinson's disease: a functional MRI study. PLoS One 2013 0.81
117 mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. Exp Neurol 2010 0.81
118 Association between migraine and headache attributed to stroke: a case-control study. Headache 2008 0.81
119 Ictal epileptic headache mimicking status migrainosus: EEG and DWI-MRI findings. Headache 2011 0.81
120 Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol Dis 2002 0.80
121 Stimulus frequency, calcium levels and striatal synaptic plasticity. Neuroreport 2003 0.80
122 Role of the dorsal hippocampus in object memory load. Learn Mem 2012 0.80
123 Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. Eur J Pharmacol 2006 0.80
124 Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation. Neuroreport 2002 0.80
125 Behavioural learning-induced increase in spontaneous GABAA-dependent synaptic activity in rat striatal cholinergic interneurons. Eur J Neurosci 2003 0.80
126 Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. J Neurol 2010 0.80
127 Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease? Mov Disord 2014 0.79
128 Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission. J Cereb Blood Flow Metab 2012 0.79
129 Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease. J Neurol 2011 0.79
130 Occipital pseudoaneurysm as a complication of extension channel placement for DBS in Parkinson's disease. Mov Disord 2007 0.79
131 Language disturbances as a side effect of prophylactic treatment of migraine. Headache 2008 0.79
132 Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease? Lancet Neurol 2007 0.79
133 Calcium signaling and neuronal vulnerability to ischemia in the striatum. Cell Calcium 2004 0.78
134 Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. Cephalalgia 2011 0.78
135 Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proc Natl Acad Sci U S A 2013 0.78
136 Multiple cranial nerve palsies in a patient with internal carotid artery dissection. Eur Neurol 2007 0.78
137 Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. Neurobiol Dis 2004 0.78
138 Levetiracetam protects against kainic acid-induced toxicity. Life Sci 2004 0.78
139 Θ-burst stimulation and striatal plasticity in experimental parkinsonism. Exp Neurol 2012 0.78
140 The endocannabinoid system in Parkinson's disease. Curr Pharm Des 2008 0.78
141 Endogenous dopamine amplifies ischemic long-term potentiation via D1 receptors. Stroke 2002 0.78
142 N-methyl-D-aspartate (NMDA) receptor composition modulates dendritic spine morphology in striatal medium spiny neurons. J Biol Chem 2012 0.78
143 A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. J Alzheimers Dis 2010 0.78
144 TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid. Neuropsychopharmacology 2010 0.77
145 The Project for a Scientific Psychology (1895): a Freudian anticipation of LTP-memory connection theory. Brain Res Brain Res Rev 2004 0.77
146 Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 2008 0.77
147 A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol 2009 0.77
148 Protective effects of zonisamide against rotenone-induced neurotoxicity. Neurochem Res 2013 0.77
149 Mutant huntingtin goes straight to the heart. Nat Neurosci 2002 0.77
150 Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. Parkinsons Dis 2012 0.77
151 Rhes-mTORC1 interaction: a new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia? Mov Disord 2012 0.76
152 L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias? Ann Neurol 2010 0.76
153 L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. Neurosci Lett 2006 0.76
154 Vomiting due to intravenous levetiracetam in a case of Creutzfeldt-Jakob disease. Epilepsy Behav 2009 0.76
155 Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. Ann Neurol 2015 0.76
156 Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. BMC Neurol 2007 0.76
157 Engagement of rat striatal neurons by cortical epileptiform activity investigated with paired recordings. J Neurophysiol 2004 0.76
158 Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 2006 0.76
159 Erratum: Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Sci Rep 2016 0.76
160 Neuroscience: Brain's traffic lights. Nature 2010 0.76
161 A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. Cephalalgia 2013 0.76
162 Diagnostic accuracy of Parkinson disease by support vector machine (SVM) analysis of 123I-FP-CIT brain SPECT data: implications of putaminal findings and age. Medicine (Baltimore) 2014 0.76
163 NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Exp Neurol 2006 0.76
164 Na+/Ca2+ exchanger maintains ionic homeostasis in the peri-infarct area. Stroke 2007 0.76
165 Rhes, a key element of selective neuronal vulnerability in Huntington's disease: a striatal-specific license to kill during energy metabolism failure. Mov Disord 2013 0.76
166 Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. Neuromolecular Med 2012 0.76
167 The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients. Parkinsonism Relat Disord 2012 0.75
168 Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. Epilepsy Res 2008 0.75
169 Myostatin depletion: a therapy for Ehlers-Danlos syndrome? Ann Neurol 2010 0.75
170 Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance. Mov Disord 2010 0.75
171 Migraine with aura in the locker room: three case reports. J Headache Pain 2011 0.75
172 Prenatal stress and hippocampal BDNF expression: a fading imperative. J Physiol 2012 0.75
173 Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. Eur Neurol 2016 0.75
174 Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients. Mult Scler 2013 0.75
175 Giant basilar apex aneurysm presenting as bilateral thalamic compression with neuropsychological disorders. Eur Neurol 2006 0.75
176 Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina. Exp Brain Res 2006 0.75
177 Scientific research of Italian neurologists from 2008 to 2011. Neurol Sci 2013 0.75
178 The validation of an Italian version of the Freezing of Gait Questionnaire. Neurol Sci 2014 0.75
179 Seizure aggravation caused by antiepileptic drugs in a patient with muscle-eye-brain disease. Epilepsy Behav 2010 0.75
180 Acute dystonia induced by the combination of midodrine and perphenazine. J Neurol 2008 0.75
181 A young patient with type C multiple system atrophy and hereditary hemochromatosis. J Neurol 2009 0.75
182 Palinopsia in patients with migraine: a case-control study. Cephalalgia 2011 0.75